John C. Byrd

City Of Hope National Medical Center — United States

Medicine · Health Sciences

25h-index6.1kcitations264works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(118), Acute Myeloid Leukemia Research(94), Chronic Myeloid Leukemia Treatments(52), Lymphoma Diagnosis and Treatment(40), Acute Lymphoblastic Leukemia research(18)

Publications264 total

Supplementary Figure S1 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Data from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S8 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S5 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S6 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S3 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S7 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S10 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S2 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Figure S4 from Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
2025Open Access
Supplementary Table S1 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
2025Open Access
Supplementary table S2 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
2025Open Access
Supplementary Methods S1 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
2025Open Access
Supplementary Table S3 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
2025Open Access
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study
Clinical Cancer Research·2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy
Haematologica·2025· 1 citedOpen Access
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Blood Cancer Discovery·2025· 1 cited
Loss of the Y chromosome defines a biologically distinct subtype of Acute Myeloid Leukemia (AML), associated with decreased inflammatory response patterns, and favorable outcomes in young male patients (pts)
Blood·2025
A healthy volunteer study with lomonitinib predicts pharmacokinetics and pharmacodynamics in a relapsed refractory AML study
Blood·2025
Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)
Blood·2025
page 1 of 14Next →

Frequent Co-authors

Jennifer A. Woyach(14), Michael R. Grever(12), Kerry A. Rogers(8), Guido Marcucci(7), Seema A. Bhat(6), Ian W. Flinn(5), William Blum(5), Cecelia Miller(5), Deborah M. Stephens(5), Kristie A. Blum(4), Gerard Lozanski(4), David Lucas(4), Farrukh T. Awan(4), Adam S. Kittai(4), Amy S. Ruppert(4), Nyla A. Heerema(4), Jeffrey A. Jones(4), James S. Blachly(4), Wendy Stock(4), Ying Huang(4)